A5035860973- Pelvic floor disorders treatments
- Urinary Bladder and Prostate Research
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Ureteral procedures and complications
- Anorectal Disease Treatments and Outcomes
- Bladder and Urothelial Cancer Treatments
- Urinary Tract Infections Management
- Botulinum Toxin and Related Neurological Disorders
- Sexual function and dysfunction studies
- Pediatric Urology and Nephrology Studies
- Urinary and Genital Oncology Studies
- Urologic and reproductive health conditions
- Health, Medicine and Society
- Prostate Cancer Treatment and Research
- Spinal Dysraphism and Malformations
- Renal cell carcinoma treatment
- COVID-19 and healthcare impacts
- Hormonal and reproductive studies
- Diverticular Disease and Complications
- Pelvic and Acetabular Injuries
- Hernia repair and management
- Kidney Stones and Urolithiasis Treatments
- Cardiovascular Syncope and Autonomic Disorders
- Anesthesia and Pain Management
Pitié-Salpêtrière Hospital
2016-2025
Sorbonne Université
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Physiopathologie et Epidémiologie des Maladies Respiratoires
2025
Inserm
2017-2025
Onco-Urologie Prédictive
2021-2025
Université Paris Cité
2003-2024
Laboratoire National de Référence
2024
Université Paris 1 Panthéon-Sorbonne
2024
Université de Versailles Saint-Quentin-en-Yvelines
2007-2023
We determined the safety and efficacy of each 2 doses botulinum toxin type A (BTX-A) (200 or 300 U BOTOX) injected into detrusor for urinary incontinence caused by neurogenic overactivity predominantly spinal cord origin.A total 59 patients with (due to injury in 53 multiple sclerosis 6) requiring clean intermittent self-catheterization were randomized receive a single dose BTX-A U) placebo. Changes daily frequency episodes monitored via patient bladder diary during 24 weeks. Key urodynamic...
No AccessJournal of UrologyAdult Urology1 Jan 2009Long-Term Outcomes After Nephron Sparing Surgery for Renal Cell Carcinoma Larger Than 4 cm Matthieu Peycelon, Vincent Hupertan, Eva Comperat, Raphaële Renard-Penna, Christophe Vaessen, Pierre Conort, Marc-Olivier Bitker, Emmanuel Chartier-Kastler, François Richard, and Morgan Rouprêt PeycelonMatthieu Peycelon Department Urology, Groupement Hospitalier Universitaire Est (Pitié-Tenon), Assistance-Publique Hôpitaux de Paris Faculté Médecine et...
Sacral neuromodulation (SNM) is an accepted therapy for a variety of conditions. However, despite over 20 years experience, it remains specialized procedure with number subtleties. Here we present the recommendations issued from International Continence Society (ICS) SNM Consensus Panel.Under auspices ICS, eight urologists, three colorectal surgeons and two urogynecologists, covering wide breadth geographic specialty interest representation, met in January 2017 to discuss best practices...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2000LONG-TERM RESULTS OF SACRAL NERVE STIMULATION (S3) FOR THE TREATMENT NEUROGENIC REFRACTORY URGE INCONTINENCE RELATED TO DETRUSOR HYPERREFLEXIA EMMANUEL J. CHARTIER-KASTLER, J.L. H. RUUD BOSCH, MICHEL PERRIGOT, MICHAEL B. CHANCELLOR, FRANÇOIS RICHARD, and PIERRE DENYS CHARTIER-KASTLEREMMANUEL CHARTIER-KASTLER , BOSCHJ.L. BOSCH PERRIGOTMICHEL PERRIGOT CHANCELLORMICHAEL CHANCELLOR RICHARDFRANÇOIS RICHARD DENYSPIERRE View...
Spinal cord injury (SCI) patients with neurogenic bladder have an increased risk for symptomatic urinary tract infection (UTI). Recurrent UTI requires multiple courses of antibiotic therapy, markedly increasing the incidence multidrug-resistant (MDR) bacteria.During observational prospective study, we determined safety and efficacy a weekly oral cyclic (WOCA) regimen to prevent in SCI adult undergoing clean intermittent catheterization. The WOCA consisted alternate administration once per...